Additional Guidance on the Use of the PRESERFLO™ MicroShunt in the Treatment of Glaucoma: Insights from a Second Delphi Consensus Panel

Simple item page
dc.contributor.authorKhawaja, Anthony P.
dc.contributor.authorAbegão Pinto, Luís
dc.contributor.authorStalmans, Ingeborg
dc.contributor.authorAptel, Florent
dc.contributor.authorBarkander, Anna
dc.contributor.authorBarton, Keith
dc.contributor.authorBeckers, Henny
dc.contributor.authorIliev, Milko
dc.contributor.authorKlink, Thomas
dc.contributor.authorMarchini, Giorgio
dc.contributor.authorMartínez De La Casa Fernández-Borrella, José María
dc.contributor.authorPillunat, Karin R
dc.contributor.authorSimonsen, Jan H
dc.contributor.authorVass, Clemens
dc.date.accessioned2024-05-24T19:08:46Z
dc.date.available2024-05-24T19:08:46Z
dc.date.issued2024-04-08
dc.descriptionReceived: 16 November 2023; Accepted: 29 January 2024; Published: 08 April 2024; Issue Date: June 2024
dc.description.abstractIntroduction: The PRESERFLO™ MicroShunt (PMS) has been proven to significantly lower intraocular pressure (IOP) in patients with glaucoma and has been available for use since 2019. With increasing published evidence and growing experience of glaucoma surgeons, the aim of this modified Delphi panel was to build on the findings of a previous Delphi panel conducted in 2021 and provide further guidance on the role of the PMS to treat patients with glaucoma in Europe. Methods: Thirteen European glaucoma surgeons experienced in the PMS procedure participated in a 3-round modified Delphi panel. A targeted literature review and expert steering committee guided Round 1 questionnaire development. Consensus was pre-defined at a threshold of ≥ 70% of panellists selecting 'strongly agree'/'agree' or 'strongly disagree'/'disagree' for 6-point Likert scale questions or ≥ 70% selecting the same option for multiple or single-choice questions. Questions not reaching consensus were restated/revised for the next round, following guidance from free-text responses/scoping questions. Results: In total, 28% (n = 9/32), 52% (n = 16/31) and 91% (n = 10/11) of statements reached consensus in Rounds 1, 2 and 3, respectively. There was agreement that the PMS may be used in patients with pigmentary, post-trauma or post-vitrectomy glaucoma and for patients with uveitic glaucoma without active inflammation. The PMS may be more suitable for patients with contact lenses than other subconjunctival filtering surgeries, without eliminating bleb-associated risks. Consensus was reached that combining PMS implantation and phacoemulsification may be as safe as standalone PMS surgery, but further efficacy data are required. Following a late rise in IOP ≥ 4 months post-surgery, topical aqueous suppressant drops or bleb revision may be suitable management options. Conclusions: This Delphi panel builds on the considerations explored in the 2021 Delphi panel and provides further detailed guidance for glaucoma surgeons on the use of the PMS, reflecting the availability of novel evidence and surgical experience. Videos are available for this article.
dc.description.departmentUnidad Docente de Inmunología, Oftalmología y ORL
dc.description.facultyFac. de Óptica y Optometría
dc.description.fundingtypePagado por el autor
dc.description.refereedTRUE
dc.description.sponsorshipSanten SA
dc.description.sponsorshipLister Institute
dc.description.sponsorshipAlcon Research Institute
dc.description.sponsorshipUK Research and Innovation
dc.description.statuspub
dc.identifier.citationKhawaja AP, Abegão Pinto L, Stalmans I, Aptel F, Barkander A, Barton K, Beckers H, Iliev M, Klink T, Marchini G, Martínez de la Casa J, Pillunat KR, Simonsen JH, Vass C. Additional Guidance on the Use of the PRESERFLO™ MicroShunt in the Treatment of Glaucoma: Insights from a Second Delphi Consensus Panel. Ophthalmol Ther. 2024 Apr 8. doi: 10.1007/s40123-024-00902-5. Epub ahead of print. PMID: 38587774.
dc.identifier.doi10.1007/s40123-024-00902-5
dc.identifier.essn2193-6528
dc.identifier.issn2193-8245
dc.identifier.officialurlhttps://doi.org/10.1007/s40123-024-00902-5
dc.identifier.pmid38587774
dc.identifier.relatedurlhttps://link.springer.com/article/10.1007/s40123-024-00902-5
dc.identifier.urihttps://hdl.handle.net/20.500.14352/104442
dc.journal.titleOphthalmology and Therapy
dc.language.isoeng
dc.page.final1588
dc.page.initial1569
dc.publisherSpringer Nature
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.cdu617.7-007.681
dc.subject.cdu617.749-089
dc.subject.cdu612.842.6
dc.subject.keywordConsensus
dc.subject.keywordGlaucoma
dc.subject.keywordGlaucoma surgery
dc.subject.keywordIntraocular pressure
dc.subject.keywordMIGS
dc.subject.keywordMicroShunt
dc.subject.keywordPRESERFLO™
dc.subject.ucmOftalmología
dc.subject.ucmCirugía
dc.subject.unesco3201.09 Oftalmología
dc.subject.unesco3213.09 Cirugía Ocular
dc.titleAdditional Guidance on the Use of the PRESERFLO™ MicroShunt in the Treatment of Glaucoma: Insights from a Second Delphi Consensus Panel
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication
relation.isAuthorOfPublication273a99c3-2c9f-4dd0-8939-b7ff3593124c
relation.isAuthorOfPublication.latestForDiscovery273a99c3-2c9f-4dd0-8939-b7ff3593124c
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Additional_Guidance_PRESERFLO_MicroShunt_2024.pdf
Size:
1.12 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos